Agilent PD-L1 assay FDA approved as CDx

Create PDF

Agilent developed the assay in 2016 through a collaboration with Bristol Myers Squibb; it was previously approved as a complementary in vitro diagnostic for non-squamous non-small cell lung cancer, as well as for squamous cell carcinoma of the head and neck, and urothelial carcinoma. Opdivo and Yervoy are manufactured by Bristol-Myers Squibb.